Séminaires CRCL-CLB

Séminaires CRCL-CLB

Séminaire médico-scientifique CRCL/CLB


Le prochain séminaire médico-scientifique CRCL/CLB se tiendra le vendredi 5 mai à 11h30  dans la salle ONCORA (Centre Léon Bérard, 2e étage). Nous serons heureux d'accueillir 
le Pr Cathrin Brisken (EPFL Lausanne). Plus d'informations prochainement.
Evènements scientifiques - 2017

Evènements scientifiques - 2017

Save the date :
4th ANRS HBV Cure Workshop
May 16th 2017 - Espace Saint-Martin - 75003 Paris -
Preliminary program click here

Le 3e Symposium CRCL 2017 vous donne rendez-vous les 25-27 septembre 2017 ! Découvrez le nouveau site web dédié en cliquant ici.




MANY THANKS !
The 1st International Symposium "Immune Responses in Cancer and Infection" jointly organized by the CRCL and the CIRI (International Research Centre in Infectiology) took place recently in Lyon. It was a great pleaser to welcome 20 international speakers as well as a total of 380 participants! We thank our sponsors and partners which help us to organize this event! Many thanks again.
We can still access to the final program: click here


Informations scientifiques

Informations scientifiques

A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability

mardi 11 avril 2017
Morel AP et al. Nature Medecine Avril 2017. Cette publication est issue des travaux de l'équipe d'Alain Puisieux.
Chromosomal instability (CIN), a feature of most adult neoplasms from their early stages onward, is a driver of tumorigenesis. However, several malignancy subtypes, including some triple-negative breast cancers, display a paucity of genomic aberrations, thus suggesting that tumor development may occur in the absence of CIN. Here we show that the differentiation status of normal human mammary epithelial cells dictates cell behavior after an oncogenic event and predetermines the genetic routes toward malignancy. Whereas oncogene induction in differentiated cells induces massive DNA damage, mammary stem cells are resistant, owing to a preemptive program driven by the transcription factor ZEB1 and the methionine sulfoxide reductase MSRB3. The prevention of oncogene-induced DNA damage precludes induction of the oncosuppressive p53-dependent DNA-damage response, thereby increasing stem cells' intrinsic susceptibility to malignant transformation. In accord with this model, a subclass of breast neoplasms exhibit unique pathological features, including high ZEB1 expression, a low frequency of TP53 mutations and low CIN.
PubMed access: click here

Structural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical Implications in Cancers

vendredi 25 mars 2016
This study involves the team of Patrick Mehlen.
Netrin-1 has been shown to be up-regulated in a fraction of human cancers as a mechanism to allow these tumors to escape the pro-apoptotic activity of some of its main dependence receptors, the UNC5 homologs (UNC5H). Here we identify the V-2 domain of netrin-1 to be important for its interaction with the Ig1/Ig2 domains of UNC5H2. We generate a humanized anti-netrin-1 antibody that disrupts the interaction between netrin-1 and UNC5H2 and triggers death of netrin-1-expressing tumor cells in vitro. We also present evidence that combining the anti-netrin-1 antibody with epidrugs such as decitabine could be effective in treating tumors showing no or modest netrin-1 expression. These results support that this antibody is a promising drug candidate.
PubMed access: click here

Autres actualités

Mars 2017
Communiqué de presse :
4P-PHARMA ET PULSALYS ÉTABLISSENT UN ACCORD DE CO-MATURATION POUR LE DÉVELOPPEMENT D’UN MÉDICAMENT INNOVANT DANS LE TRAITEMENT DU CANCER (équipe R. Rimokh et G. Gillet). Cliquez ici

Janvier 2017

Communiqué de presse : SANOFI-INSERM HBV Cure program: a medical, academic and pharmaceutical alliance for research on Hepatitis B. Cliquez ici

Création d'un Laboratoire International Associé (LIA) entre l'équipe CRCL d'Alain Puisieux "EMT et plasticité des cellules cancéreuses" et l'équipe de  Frédéric Hollande "Molecular Mechanisms of Tumour Progression" du Victorian Comprehensive Cancer Centre (Université de Melbourne, Australie).
Offres d'emploi

Offres d'emploi

Plusieurs postes sont à pourvoir au CRCL : cliquez ici

Mars 2017
Un poste en CDD est à pourvoir dans le groupe de F. Tirode :
cliquez ici
February 2017
A postdoc position in onco-immunology is available in C. Caux's lab : click here
January 2017

Postdoc in tumor immunology: click here
December 2016
A postdoc position
in the team of F. Zoulim : click here
Other positions
- Other postdoc positions are available in the teams of M. Gabut and J. Marie: click here

Suivez-nous sur Twitter !

Suivez les actualités du CRCL sur notre compte Twitter !

Vidéo Equipe I Chemin/P Merle